Angiotensin Receptor Blockers (ARBs): Ongoing Safety Review for Cancer Risk
The FDA is reviewing the safety of angiotensin-receptor blockers after a recent meta-analysis suggested a small increase in new cancer diagnoses in patients using the drugs.
The agency will update the public with its conclusions as soon as the review is complete. In the meantime, it says the benefits of ARBs outweigh any potential risks, and it advises that the drugs continue to be used as recommended.
Clinicians should report any ARB-related adverse events to the FDA's MedWatch program.
FDA MedWatch
No comments:
Post a Comment